^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Ewing Sarcoma
    Regimen:VDC (cyclophosphamide + doxorubicin hydrochloride + vincristine)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    11/20/2020
    Excerpt:
    Ewing sarcoma: First-line therapy (primary/neoadjuvant/adjuvant therapy)…Preferred Regimens…VDC/IE (vincristine, doxorubicin, and cyclophosphamide alternating with ifosfamide and etoposide)
    Secondary therapy:
    IE
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Ewing sarcoma: Primary therapy for metastatic disease at initial presentation…VDC